Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

USA - NASDAQ:RCEL - US05380C1027 - Common Stock

3.41 USD
-0.09 (-2.57%)
Last: 11/6/2025, 1:26:47 PM
Fundamental Rating

3

Taking everything into account, RCEL scores 3 out of 10 in our fundamental rating. RCEL was compared to 534 industry peers in the Biotechnology industry. RCEL may be in some trouble as it scores bad on both profitability and health. RCEL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RCEL has reported negative net income.
In the past year RCEL has reported a negative cash flow from operations.
In the past 5 years RCEL always reported negative net income.
In the past 5 years RCEL always reported negative operating cash flow.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RCEL has a worse Return On Assets (-88.71%) than 72.85% of its industry peers.
Industry RankSector Rank
ROA -88.71%
ROE N/A
ROIC N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

RCEL has a Operating Margin of 245.35%. This is amongst the best in the industry. RCEL outperforms 100.00% of its industry peers.
RCEL has a better Gross Margin (392.18%) than 99.81% of its industry peers.
In the last couple of years the Gross Margin of RCEL has grown nicely.
Industry RankSector Rank
OM 245.35%
PM (TTM) N/A
GM 392.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCEL remains at a similar level compared to 1 year ago.
The debt/assets ratio for RCEL is higher compared to a year ago.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RCEL has an Altman-Z score of 2.72. This is not the best score and indicates that RCEL is in the grey zone with still only limited risk for bankruptcy at the moment.
RCEL's Altman-Z score of 2.72 is fine compared to the rest of the industry. RCEL outperforms 69.10% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.72
ROIC/WACCN/A
WACC10.16%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RCEL has a Current Ratio of 0.58. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.58, RCEL is not doing good in the industry: 92.32% of the companies in the same industry are doing better.
A Quick Ratio of 0.46 indicates that RCEL may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.46, RCEL is doing worse than 92.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.46
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

RCEL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
Looking at the last year, RCEL shows a very strong growth in Revenue. The Revenue has grown by 38.31%.
RCEL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.02% yearly.
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)38.31%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.21%

3.2 Future

The Earnings Per Share is expected to grow by 30.56% on average over the next years. This is a very strong growth
Based on estimates for the next years, RCEL will show a very strong growth in Revenue. The Revenue will grow by 39.17% on average per year.
EPS Next Y46.94%
EPS Next 2Y31.57%
EPS Next 3Y25.09%
EPS Next 5Y30.56%
Revenue Next Year14.01%
Revenue Next 2Y23.11%
Revenue Next 3Y37.12%
Revenue Next 5Y39.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCEL. In the last year negative earnings were reported.
Also next year RCEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RCEL is valued cheaper than 99.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.63
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

RCEL's earnings are expected to grow with 25.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.57%
EPS Next 3Y25.09%

More info and screens

0

5. Dividend

5.1 Amount

RCEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (11/6/2025, 1:26:47 PM)

3.41

-0.09 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners29.23%
Inst Owner Change0.43%
Ins Owners0.85%
Ins Owner Change3.01%
Market Cap90.77M
Revenue(TTM)74.88M
Net Income(TTM)-51573000
Analysts75.38
Price Target7.65 (124.34%)
Short Float %11.99%
Short Ratio4.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.59%
Min EPS beat(2)-50.22%
Max EPS beat(2)-34.96%
EPS beat(4)1
Avg EPS beat(4)-31.02%
Min EPS beat(4)-50.22%
Max EPS beat(4)0.41%
EPS beat(8)3
Avg EPS beat(8)-17.16%
EPS beat(12)5
Avg EPS beat(12)-11.92%
EPS beat(16)9
Avg EPS beat(16)-0.84%
Revenue beat(2)0
Avg Revenue beat(2)-17.14%
Min Revenue beat(2)-20.13%
Max Revenue beat(2)-14.15%
Revenue beat(4)0
Avg Revenue beat(4)-12.47%
Min Revenue beat(4)-20.13%
Max Revenue beat(4)-1.35%
Revenue beat(8)2
Avg Revenue beat(8)-6.77%
Revenue beat(12)6
Avg Revenue beat(12)-1.55%
Revenue beat(16)9
Avg Revenue beat(16)0.25%
PT rev (1m)-14.77%
PT rev (3m)-53.49%
EPS NQ rev (1m)-9.23%
EPS NQ rev (3m)-122.74%
EPS NY rev (1m)-18.87%
EPS NY rev (3m)-81.82%
Revenue NQ rev (1m)-10.12%
Revenue NQ rev (3m)-30.8%
Revenue NY rev (1m)-2.04%
Revenue NY rev (3m)-23.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.63
EPS(TTM)-1.97
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS2.81
BVpS-0.48
TBVpS-0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -88.71%
ROE N/A
ROCE -4112.02%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 245.35%
PM (TTM) N/A
GM 392.18%
FCFM N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score4
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 341.35%
Cap/Sales 8.17%
Interest Coverage 31.61
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.46
Altman-Z 2.72
F-Score4
WACC10.16%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next Y46.94%
EPS Next 2Y31.57%
EPS Next 3Y25.09%
EPS Next 5Y30.56%
Revenue 1Y (TTM)38.31%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.21%
Revenue Next Year14.01%
Revenue Next 2Y23.11%
Revenue Next 3Y37.12%
Revenue Next 5Y39.17%
EBIT growth 1Y440.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.22%
EBIT Next 3Y23.94%
EBIT Next 5Y22.45%
FCF growth 1Y-66.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.98%
OCF growth 3YN/A
OCF growth 5YN/A

AVITA MEDICAL INC / RCEL FAQ

What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RCEL.


What is the valuation status for RCEL stock?

ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.


Can you provide the profitability details for AVITA MEDICAL INC?

AVITA MEDICAL INC (RCEL) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for RCEL stock?

The Earnings per Share (EPS) of AVITA MEDICAL INC (RCEL) is expected to grow by 46.94% in the next year.